Laboratory biomarkers of cardiac involvement in systemic sclerosis. Part 2
https://doi.org/10.14412/1996-7012-2026-3-7-11
Abstract
Systemic sclerosis (SSc) is characterized by multisystem involvement and represents a serious clinical challenge for physicians and patients. Among the visceral manifestations of SSc, primary cardiac involvement is one of the most severe and is often diagnosed late. Biomarker assessment can make a major contribution to the early diagnosis of cardiopathy in SSc.
The second part of the article is devoted to the potential use of various cytokines and other molecules for diagnosis and prognostic assessment of primary cardiac involvement associated with SSc.
About the Authors
L. A. Garzanova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Lyudmila Aleksandrovna Garzanova
34A, Kashirskoe Shosse, Moscow 115522
L. P. Ananyeva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
O. A. Koneva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
O. B. Ovsyannikova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
References
1. Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017 Oct;390(10103):1685-1699. doi:10.1016/S0140-6736(17)30933-9.
2. Nadel A, Nadel M, Taborska N, et al. Heart involvement in patients with systemic sclerosis-what have we learned about it in the last 5 years. Rheumatol Int. 2024 Oct;44(10): 1823-1836. doi:10.1007/s00296-024-05699-x.
3. Agoston-Coldea L, Zlibut A, Revnic R, et al. Current advances in cardiac magnetic resonance imaging in systemic sclerosis. Eur Rev Med Pharmacol Sci. 2021 May;25(10):3718- 3736. doi:10.26355/eurrev_202105_25940.
4. Bruni C, Buch MH, Furst DE, et al. Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition. J Scleroderma Relat Disord. 2022 Feb; 7(1):24-32. doi:10.1177/23971983211053246.
5. Krumm P, Mueller KA, Klingel K, et al. Cardiovascular magnetic resonance patterns of biopsy proven cardiac involvement in systemic sclerosis. J Cardiovasc Magn Reson. 2016 Oct 21;18(1):70. doi:10.1186/s12968-016-0289-3.
6. Allanore Y, Meune C, Vonk MC, et al. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis. 2010 Jan;69(1):218-21. doi:10.1136/ard.2008.103382.
7. Bruni C, Buch MH, Djokovic A, et al. Consensus on the assessment of systemic sclerosis-associated primary heart involvement: World Scleroderma Foundation/Heart Failure Association guidance on screening, diagnosis, and follow-up assessment. J Scleroderma Relat Disord. 2023 Oct;8(3):169-182. doi:10.1177/23971983231163413.
8. Smolenska Z, Barraclough R, Dorniak K, et al. Cardiac Involvement in Systemic Sclerosis: Diagnostic Tools and Evaluation Methods. Cardiol Rev. 2019 Mar/Apr;27(2):73- 79. doi:10.1097/CRD.0000000000000221.
9. Moore DF, Steen VD. Overall mortality. J Scleroderma Relat Disord. 2021 Feb;6(1): 3-10. doi:10.1177/2397198320924873.
10. Moysidou GS, Dara A, Arvanitaki A, et al. Understanding and managing cardiac involvement in systemic sclerosis. Expert Rev Clin Immunol. 2023 Mar; 19 (3): 293-304. doi:10.1080/1744666X.2023.2171988.
11. Nie LY, Wang XD, Zhang T, Xue J. Cardiac complications in systemic sclerosis: early diagnosis and treatment. Chin Med J (Engl). 2019 Dec;132(23):2865-2871. doi:10.1097/CM9.0000000000000535.
12. Thygesen K, Alpert JS, Jaffe AS, et al. Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol. 2018 Oct 30;72(18):2231-2264. doi:10.1016/j.jacc.2018.08.1038.
13. Hughes M, Lilleker JB, Herrick AL, Chinoy H. Cardiac troponin testing in idiopathic inflammatory myopathies and systemic sclerosis-spectrum disorders: biomarkers to distinguish between primary cardiac involvement and low-grade skeletal muscle disease activity. Ann Rheum Dis. 2015 May;74(5):795-8. doi: 10.1136/annrheumdis-2014-206812.
14. Erlacher P, Lercher A, Falkensammer J, et al. Cardiac troponin and beta-type myosin heavy chain concentrations in patients with polymyositis or dermatomyositis. Clin Chim Acta. 2001 Apr;306(1-2):27-33. doi:10.1016/s0009-8981(01)00392-8.
15. Dinser R, Frerix M, Meier FM, et al. Endo cardial and myocardial involvement in systemic sclerosis – is there a relevant inflammatory component? Joint Bone Spine. 2013 May;80(3):320-3. doi:10.1016/j.jbspin.2012.10.009.
16. Vasta B, Flower V, Bucciarelli-Ducci C, et al. Abnormal cardiac enzymes in systemic sclerosis: a report of four patients and review of the literature. Clin Rheumatol. 2014 Mar; 33(3):435-8. doi:10.1007/s10067-013-2405-1.
17. Avouac J, Meune C, Chenevier-Gobeaux C, et al. Cardiac biomarkers in systemic sclerosis: contribution of high-sensitivity cardiac troponin in addition to N-terminal pro-brain natriuretic peptide. Arthritis Care Res (Hoboken). 2015 Jul;67(7):1022-30. doi:10.1002/acr.22547.
18. Nordin A, Svenungsson E, Björnеdal L, et al. Troponin I and echocardiography in patients with systemic sclerosis and matched population controls. Scand J Rheumatol. 2017 May;46(3):226-235. doi:10.1080/03009742. 2016.1192217.
19. Paik JJ, Choi DY, Mukherjee M, et al. Troponin elevation independently associates with mortality in systemic sclerosis. Clin Exp Rheumatol. 2022 Oct;40(10):1933-1940. doi:10.55563/clinexprheumatol/fytfmy.
20. Bosello S, De Luca G, Berardi G, et al. Cardiac troponin T and NT-proBNP as diagnostic and prognostic biomarkers of primary cardiac involvement and disease severity in systemic sclerosis: A prospective study. Eur J Intern Med. 2019 Feb;60:46-53. doi:10.1016/j.ejim.2018.10.013.
21. Jha M, Wang M, Steele R, et al. NT-proBNP, hs-cTnT, and CRP predict the risk of cardiopulmonary outcomes in systemic sclerosis: Findings from the Canadian Scleroderma Research Group. J Scleroderma Relat Disord. 2022 Feb;7(1):62-70. doi:10.1177/23971983211040608.
22. Barsotti S, Stagnaro C, d'Ascanio A, et al. High sensitivity troponin might be a marker of subclinical scleroderma heart involvement: a preliminary study. J Scleroderma Relat Disord. 2017 July;2(3):183-187. doi:10.5301/jsrd.5000244.
23. Kudo A, Kii I. Periostin function in communication with extracellular matrices. J Cell Commun Signal. 2018 Mar;12(1):301-308. doi:10.1007/s12079-017-0422-6.
24. Kii I. Periostin Functions as a Scaffold for Assembly of Extracellular Proteins. Adv Exp Med Biol. 2019;1132:23-32. doi:10.1007/978-981-13-6657-4_3.
25. Ohta S, Okamoto M, Fujimoto K, et al. The usefulness of monomeric periostin as a biomarker for idiopathic pulmonary fibrosis. PLoS One. 2017 Mar 29;12(3):e0174547. doi:10.1371/journal.pone.0174547.
26. Okamoto M, Izuhara K, Ohta S, et al. Ability of Periostin as a New Biomarker of Idiopathic Pulmonary Fibrosis. Adv Exp Med Biol. 2019;1132:79-87. doi:10.1007/978-981-13-6657-4_9.
27. Yamaguchi Y, Ono J, Masuoka M, et al. Serum periostin levels are correlated with progressive skin sclerosis in patients with systemic sclerosis. Br J Dermatol. 2013 Apr;168(4): 717-25. doi:10.1111/bjd.12117.
28. Yang L, Serada S, Fujimoto M, et al. Periostin facilitates skin sclerosis via PI3K/Akt dependent mechanism in a mouse model of scleroderma. PLoS One. 2012;7(7):e41994. doi:10.1371/journal.pone.0041994.
29. De Luca G, Campochiaro C, Franchini S, et al. FRI0444 Periostin in systemic sclerosis: serum levels and skin expression of a novel possible biomarker. Ann Rheum Dis. 2018;77 (Suppl 2):751. doi:10.1136/annrheumdis-2018-eular.5975.
30. Landry NM, Cohen S, Dixon IMC. Periostin in cardiovascular disease and development: a tale of two distinct roles. Basic Res Cardiol. 2017 Nov;113(1):1. doi:10.1007/s00395-017-0659-5.
31. Kanisicak O, Khalil H, Ivey MJ, et al. Genetic lineage tracing defines myofibroblast origin and function in the injured heart. Nat Commun. 2016 Jul; 7:12260. doi:10.1038/ncomms12260.
32. El-Adili F, Lui JK, Najem M, et al. Periostin overexpression in scleroderma cardiac tissue and its utility as a marker for disease complications. Arthritis Res Ther. 2022 Nov;24(1):251. doi:10.1186/s13075-022-02943-2.
33. Cardoneanu A, Burlui AM, Macovei LA, et al. Targeting Systemic Sclerosis from Pathogenic Mechanisms to Clinical Manifestations: Why IL-6? Biomedicines. 2022 Jan;10(2):318. doi:10.3390/biomedicines10020318.
34. Abdel-Magied RA, Kamel SR, Said AF, et al. Serum interleukin-6 in systemic sclerosis and its correlation with disease parameters and cardiopulmonary involvement. Sarcoidosis Vasc Diffuse Lung Dis. 2016 Dec;33(4): 321-330.
35. Jurisic Z, Martinovic-Kaliterna D, Marasovic-Krstulovic D, et al. Relationship between interleukin-6 and cardiac involvement in systemic sclerosis. Rheumatology (Oxford). 2013 Jul;52(7):1298-302. doi:10.1093/rheumatology/ket131.
36. Lin E, Vincent FB, Sahhar J, et al. Analysis of serum interleukin (IL)-1 , IL-1 and IL-18 in patients with systemic sclerosis. Clin Transl Immunology. 2019 Apr;8(4):e1045. doi:10.1002/cti2.1045.
37. Fukayama M, Yoshizaki A, Fukasawa T, et al. Interleukin (IL)-17F and IL-17E are related to fibrosis and vasculopathy in systemic sclerosis. J Dermatol. 2020 Nov; 47(11): 1287-1292. doi:10.1111/1346-8138.15508.
38. Kosalka-Wegiel J, Licholai S, PacholczakMadej R, et al. Serum IL-17 and TNF as prognostic biomarkers in systemic sclerosis patients: a prospective study. Rheumatol Int. 2024 Jan; 44(1):119-128. doi:10.1007/s00296-023-05499-9.
39. Bayes-Genis A, Zhang Y, Ky B. ST2 and patient prognosis in chronic heart failure. Am J Cardiol. 2015 Apr;115(7 Suppl):64B-9B. doi:10.1016/j.amjcard.2015.01.043.
40. Iannazzo F, Pellicano C, Colalillo A, et al. Interleukin-33 and soluble suppression of tumorigenicity 2 in scleroderma cardiac involvement. Clin Exp Med. 2023 Jul; 23(3):897-903. doi:10.1007/s10238-022-00864-7.
41. Vertes V, Porpaczy A, Nogradi Б, et al. Galectin-3 and sST2: associations to the echocardiographic markers of the myocardial mechanics in systemic sclerosis – a pilot study. Cardiovasc Ultrasound. 2022 Jan 18; 20(1):1. doi:10.1186/s12947-022-00272-7.
42. Karadag DT, Sahin T, Tekeoglu S, et al. Evaluation of left and right ventricle by twodimensional speckle tracking echocardiography in systemic sclerosis patients without overt cardiac disease. Clin Rheumatol. 2020 Jan; 39(1): 37-48. doi:10.1007/s10067-019-04604-3.
43. Gieszczyk K, Sikora-Puz A, Mizia M, et al. GDF15 and TGFB1 in patients with SSc and early remodeling of the cardiovascular system. Eur.Heart J. 2013 Aug; 34(Suppl 1):P2437. doi:10.1093/eurheartj/eht308.P2437.
44. Hromadka M, Seidlerova J, Suchy D, et al. Myocardial fibrosis detected by magnetic resonance in systemic sclerosis patients – Relationship with biochemical and echocardiography parameters. Int J Cardiol. 2017 Dec 15; 249:448-453. doi:10.1016/j.ijcard.2017.08.072.
45. Tennøe AH, Murbraech K, Didriksen H, et al. Serum markers of cardiac complications in a systemic sclerosis cohort. Sci Rep. 2022 Mar 18;12(1):4661. doi:10.1038/s41598-022-08815-8.
Review
For citations:
Garzanova LA, Ananyeva LP, Koneva OA, Ovsyannikova OB. Laboratory biomarkers of cardiac involvement in systemic sclerosis. Part 2. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2026;20(3):7-11. (In Russ.) https://doi.org/10.14412/1996-7012-2026-3-7-11
Views:
179
JATS XML
Email this article 
